Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiagliflozin in adults with type 2 diabetes mellitus and chronic kidney disease
ChiCTR2600135827Phase 4Not yet recruiting
- Sponsor
- Xiaoyi Central Hospital
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of janagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by Xiaoyi Central Hospital. Primary endpoints: homocysteine at week 24, high-sensitivity C-reactive protein at week 24 and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
janagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2600135827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135827.